PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse

Table 3 Relationship between PD-1 axis expression and clinicopathological features in musculoskeletal tumors

Variables		N %	PD-L1 expression			PD-L2 expression			PD-1 expression
Variables		N %	+	−	P	+	−	P	+	−	P
Sex	Male	129	32	97	0.603	36	93	0.911	30	99	0.335
Sex	Female	105	23	82		30	75		19	86
Age	≤ 20	47	15	32	0.293	19	28	0.144	9	38	0.165
	≤ 33	65	13	52		17	48		18	47
	≤ 50	75	14	61		16	59		10	65
	> 50	47	13	34		14	33		12	35
Histologic type of musculoskeletal tumor	Synovial sarcoma	127	20	107	0.000	26	101	0.004	24	103	0.000
	Osteosarcoma	62	22	40		26	36		17	45
	Chondrosarcoma	31	3	28		7	24		0	31
	Giant cell tumor	14	10	4		7	7		8	6
State of osteosarcoma*	Primary osteosarcoma	45	15	30	0.225	18	27	0.878	10	36	0.087
	Recurrent osteosarcoma	17	7	10		8	9		7	9
	Metastatic osteosarcoma	5	0	5		2	3		0	5
Clinical stage of synovial sarcoma	G1	16	0	16	0.011	3	13	0.912	3	13	0.103
	G2-3	99	15	84		20	79		16	83
	G4	12	5	7		3	9		5	7

Abbreviations: PD-L1 programmed death ligand-1, PD-L2 programmed death ligand-2, PD-1 programmed death-1
*5 paired samples included on the array (62 osteosarcoma patients with 67 samples)

ISSN: 1756-8722